Retatrutide 30 mg reasreach only vial

Main Title

Retatrutide 30 mg — Triple GLP-1/GIP/Glucagon Receptor Agonist for Metabolic Research

Full Description

Retatrutide is a synthetic single-molecule triple agonist that simultaneously activates the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is extensively investigated in preclinical and clinical research for its potent effects on glycemic control, body weight reduction, energy expenditure, and overall cardiometabolic health in models of obesity and type 2 diabetes, showing superior efficacy compared to dual agonists in multiple studies.

What It Is

• Class: Triple incretin/glucagon receptor agonist

• Concept: Combines GLP-1 and GIP signaling with glucagon receptor activation to enhance insulin secretion, suppress appetite, increase energy expenditure, and promote significant fat loss while preserving lean mass in metabolic research models.

• Format: Research-grade synthetic peptide supplied as a lyophilized powder.

Proposed Mechanisms (Preclinical)

Incretin & Glucagon Receptor Activation

• Potent agonist at GLP-1 and GIP receptors to enhance glucose-dependent insulin secretion and suppress glucagon.

• Activates glucagon receptors to increase energy expenditure and lipolysis.

Appetite & Energy Balance

• Acts on central hypothalamic pathways to reduce food intake and modulate satiety.

• Balances glucagon-mediated increases in energy expenditure with incretin effects to optimize weight loss.

Metabolic & Tissue Effects

• Investigated for improvements in insulin sensitivity, lipid metabolism, and reductions in liver fat and visceral adipose tissue.

Selected Research Highlights

• Weight Management: Produced substantial body weight reductions (often exceeding dual agonists) in obesity models through combined appetite suppression and increased energy expenditure.

• Glycemic Control: Demonstrated robust improvements in HbA1c, fasting glucose, and glucose tolerance in type 2 diabetes research models.

• Body Composition: Associated with significant fat mass reduction while helping preserve lean muscle mass.

• Cardiometabolic Benefits: Studied for favorable effects on lipids, liver fat (NAFLD/NASH models), and other cardiovascular risk markers.

• Triple Agonism Advantage: Showed superior efficacy compared to dual GLP-1/GIP agonists in head-to-head preclinical and translational studies.

• Long-Acting Profile: Engineered for sustained activity suitable for once-weekly administration in research settings.

Chemical & Handling Information

• Type: Synthetic long-acting triple receptor agonist peptide

• Appearance: White to off-white lyophilized powder

Specifications

• Peptide: Retatrutide

• Amount: 10 mg per vial

• Form: Lyophilized powder

• Purity: ≥99% (HPLC) – Certificate of Analysis available per lot

• Packaging: Sealed vials suitable for standard laboratory handling

Storage & Stability

• Store lyophilized vials in a cool, dry place protected from light.

• Refrigeration or freezing of the lyophilized peptide is recommended for extended stability according to laboratory SOPs.

• After reconstitution: Store at 2–8 °C for short-term use.

• Long-term storage: Aliquot and freeze at –20 °C or below. Avoid repeated freeze-thaw cycles.